TY - JOUR
T1 - Symptomatic hyperlactataemia precipitated by the addition of tetracycline to combination antiretroviral therapy
AU - Blazes, David L.
AU - Decker, Catherine F.
PY - 2006/4
Y1 - 2006/4
N2 - Hyperlactataemia in the setting of combination antiretroviral therapy for HIV infection occurs on a spectrum ranging from common, asymptomatic laboratory abnormalities to rare, potentially life-threatening lactic acidosis. Some other medications, including the biguanides, tetracycline, and even linezolid, have rarely been reported to cause lactic acidosis. Recently, cases of lactic acidosis or hyperlactataemia have been reported in patients receiving combination antiretroviral therapy that have been precipitated by the addition of other medications - eg, metformin or ribavirin. We report a case of symptomatic hyperlactataemia in a patient on combination antiretroviral therapy that was likely precipitated by the addition of tetracycline and discuss the broader implications of other medications with the potential to cause hyperlactataemia in the setting of combination antiretroviral therapy.
AB - Hyperlactataemia in the setting of combination antiretroviral therapy for HIV infection occurs on a spectrum ranging from common, asymptomatic laboratory abnormalities to rare, potentially life-threatening lactic acidosis. Some other medications, including the biguanides, tetracycline, and even linezolid, have rarely been reported to cause lactic acidosis. Recently, cases of lactic acidosis or hyperlactataemia have been reported in patients receiving combination antiretroviral therapy that have been precipitated by the addition of other medications - eg, metformin or ribavirin. We report a case of symptomatic hyperlactataemia in a patient on combination antiretroviral therapy that was likely precipitated by the addition of tetracycline and discuss the broader implications of other medications with the potential to cause hyperlactataemia in the setting of combination antiretroviral therapy.
UR - http://www.scopus.com/inward/record.url?scp=33645101785&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(06)70440-6
DO - 10.1016/S1473-3099(06)70440-6
M3 - Review article
C2 - 16554250
AN - SCOPUS:33645101785
SN - 1473-3099
VL - 6
SP - 249
EP - 252
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 4
ER -